Bioventus Inc. (NASDAQ:BVS) Given Average Recommendation of “Buy” by Brokerages

Bioventus Inc. (NASDAQ:BVS) has been assigned an average rating of “Buy” from the six research firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $14.20.

BVS has been the subject of a number of research reports. CJS Securities initiated coverage on Bioventus in a research report on Friday, March 27th. They issued a “market outperform” rating and a $14.00 price objective for the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Bioventus in a research report on Tuesday, June 2nd. Barrington Research reiterated an “outperform” rating and issued a $14.00 price objective on shares of Bioventus in a research report on Friday, May 22nd. Canaccord Genuity Group reiterated a “buy” rating and issued a $15.00 price objective on shares of Bioventus in a research report on Tuesday. Finally, Cantor Fitzgerald upgraded Bioventus to a “strong-buy” rating in a research report on Wednesday, March 4th.

Bioventus Stock Performance

Shares of NASDAQ:BVS opened at $8.71 on Friday. The business has a fifty day moving average of $9.56 and a 200-day moving average of $8.67. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.13 and a current ratio of 1.69. The firm has a market cap of $727.59 million, a PE ratio of 21.24, a price-to-earnings-growth ratio of 1.12 and a beta of 0.67. Bioventus has a twelve month low of $5.81 and a twelve month high of $11.25.

Bioventus (NASDAQ:BVS) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.06. The firm had revenue of $132.09 million during the quarter. Bioventus had a return on equity of 29.97% and a net margin of 4.94%.Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, equities research analysts predict that Bioventus will post 0.77 EPS for the current fiscal year.

Institutional Trading of Bioventus

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC grew its position in shares of Bioventus by 4.1% during the 4th quarter. Nantahala Capital Management LLC now owns 6,047,403 shares of the company’s stock worth $44,993,000 after buying an additional 236,741 shares during the period. Vanguard Group Inc. grew its position in shares of Bioventus by 4.4% during the 3rd quarter. Vanguard Group Inc. now owns 2,924,788 shares of the company’s stock worth $19,567,000 after buying an additional 122,749 shares during the period. Royce & Associates LP grew its position in shares of Bioventus by 15.6% during the 3rd quarter. Royce & Associates LP now owns 1,262,976 shares of the company’s stock worth $8,449,000 after buying an additional 170,900 shares during the period. Geode Capital Management LLC grew its position in shares of Bioventus by 1.8% during the 4th quarter. Geode Capital Management LLC now owns 1,120,238 shares of the company’s stock worth $8,337,000 after buying an additional 19,388 shares during the period. Finally, State Street Corp grew its position in shares of Bioventus by 1.7% during the 4th quarter. State Street Corp now owns 891,024 shares of the company’s stock worth $6,629,000 after buying an additional 14,590 shares during the period. 62.94% of the stock is currently owned by institutional investors and hedge funds.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.